Recent clinical trials in China have demonstrated promising results for late-stage cancer patients using an engineered herpes simplex virus therapy known as VG161. Researchers from the First Affiliated Hospital of Zhejiang University reported that VG161 can infiltrate and dismantle drug-resistant liver tumors while enhancing the body’s immune response. In early trials involving 40 liver cancer patients, the therapy nearly doubled life expectancy, leading to approval for further research under China’s emergency breakthrough protocol.
VG161 operates by boosting the immune system and increasing the effectiveness of anti-tumor treatments. This approach offers renewed hope for terminal-stage patients, especially those for whom conventional treatments have failed. The success of VG161 underscores China’s growing role in advancing innovative cancer therapies, providing new avenues for patients with limited options. Click for More Details
